Cosmecca Korea said on the 10th that its second-quarter 2026 results came in at 226.1 billion won in revenue and 32.1 billion won in operating profit. Compared with a year earlier, revenue rose 39.8% and operating profit increased 39.3%.
The growth was largely driven by winning new clients, reorders from existing small and midsize clients, and an expanded SKU lineup all at once. The company said the so-called "snowball effect," in which the initial order leads to repeat orders and additional items, has kicked into full gear. In particular, overseas sales of K-derma skincare products leveraging research and development (R&D) capabilities increased, and the expanded export volume was reflected in results.
The Korea subsidiary led overall growth. The Korea subsidiary posted second-quarter revenue of 178.8 billion won and operating profit of 24.5 billion won. Revenue in the skincare institutional sector rose 94.8% from a year earlier. Orders for derma skincare products targeting needs by skin concerns and efficacy continued from the first quarter into the second quarter.
U.S. subsidiary Englewood Lab recorded revenue of 51.9 billion won and operating profit of 8.7 billion won in the same period. It expanded collaboration with brands entering North America by leveraging its OTC sunscreen production platform aligned with U.S. Food and Drug Administration (FDA) standards.
Through the Ready To Go (RTG) OTC turnkey solution, a rapid OTC product development program, it also increased orders from K-beauty clients. In addition, by diversifying its local U.S. beauty client portfolio, the operating margin came in at 16.8%.
China subsidiary Cosmecca China posted second-quarter revenue of 7.7 billion won and an operating loss of 1.2 billion won. However, by expanding sales focused on C-beauty and online-based clients, revenue increased 21.3% from the previous quarter. Cosmecca Korea plans to improve the China unit's profitability by adding sunscreen-centered orders to its existing cushion and primer products.
Cosmecca Korea plans to respond to related demand by using skin science-based formulation design and functional ingredient management technologies, while also expanding tailored proposals by client and follow-on product pipelines in the second half.
A Cosmecca Korea official said, "As demand for skin science-based K-derma skincare expands in the global cosmetics market, global clients' interest in our research and development capabilities and formulation technologies is also growing," adding, "We will continue to strengthen our competitiveness in the global market through technological innovation and category expansion."